Project Portfolio

Here are some of the most interesting and exciting drug discovery projects from among more than 130 underway across campus.

Contact us for more information about a project or to learn about other projects in U-M's pipeline. 

Stage Title Primary Disease Area Status
Preclinical Development A kinase inhibitor for the treatment of triple-negative breast cancer
Cancer
Active
Preclinical Development A novel compound for the treatment of lung fibrosis
Lung Disease
Partnered
Lead Optimization A small molecular compound for arthritis and bone erosion treatment
Musculoskeletal Disease
Active
Lead Optimization ALDH inhibitors to treat ovarian cancer
Cancer
Active
Clinical Trials Amlexanox for Type 2 Diabetes / Non-Alcoholic Fatty Liver Disease (NAFLD)
Diabetes, Metabolism & Endocrinology
Active
Clinical Trials ATR-101 for congenital adrenal hyperplasia (CAH)
Cancer
Partnered
Commercialized Cerdelga for Gaucher Disease
Diabetes, Metabolism & Endocrinology
Partnered
Screening Compounds that modulate autophagy
Brain & Neurological Diseases
Active
Lead Optimization Enkephalin amplifiers as novel analgesics
Pain
Active
Commercialized FluMist active immunization
Infectious Disease
Partnered
Lead Optimization Functionally blocking JAML antibodies for the treatment of inflammatory diseases
Allergy & Immune Disorder
Active
Clinical Trials Human double minute 2 (HDM2) antagonist for solid tumors
Cancer
Partnered
Lead Optimization Innovative therapy for chronic kidney disease and other indications
Kidney Disease & Urology
Partnered
Lead Optimization Mcl-1 inhibitors for the treatment of pancreatic and other cancers
Cancer
Active
Lead Optimization Monoclonal antibodies to treat metastasic cancer
Cancer
Partnered
Hit-to-Lead Nef inhibitor to treat HIV
Infectious Disease
Active
Hit-to-Lead Novel Pax2 inhibitors for renal disease
Kidney Disease & Urology
Active
Lead Optimization SHMT2 Inhibitors and Lead Compounds
Cancer
Active
Hit-to-Lead Small molecule activators of human Hsp70
Brain & Neurological Diseases
Active
Preclinical Development Targeted delivery of cancer drugs in personalized medicine
Cancer
Active